The prevalence and timing of seroconversion during pregnancy—A retrospective study to enable safe transfusion
Transfusion · 2025
DOI: 10.1111/trf.18356 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, 2025. Verfasst von E Dreyfuss und 8 weiteren Autor:innen. Beteiligte Einrichtung: Helen Schneider Hospital for Women, Rabin Medical Center, Petach Tikva, Israel. Hauptthemen laut MEDLINE: Isoantibodies, Seroconversion, Rh-Hr Blood-Group System, Blood Transfusion. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
During pregnancy, exposure to fetal red blood cell antigens can trigger alloimmunization. To enable safe transfusion of compatible blood for pregnant individuals where urgent surgery might be necessary, blood bank standards mandate a valid blood type and antibody screening every 72 h (“3‐day rule”). This practice requires frequent blood drawings contributing to patient discomfort and costs. To investigate if this practice is required, we evaluated the proportion of pregnant individuals who develop clinically significant alloantibodies within 72 h of a previous negative antibody screen. Study Design and Methods Retrospective cohort of RhD‐positive pregnant individuals with initial negative antibody screens, undergoing repeated screens at variable intervals. Seroconversion rates were compared with healthy male blood donors. Characteristics of pregnant individuals with and without seroconversion were analyzed.
Results
Among 8659 RhD‐positive pregnant individuals with initial negative antibody screens, 56 (0.6%) converted to a positive antibody screen, while only 15 (0.2%) developed clinically significant alloantibodies. Of these 15, only one converted within 3 days of testing, while others converted within 5–95 days. Two of the 15 women received a blood transfusion, 8–97 days before seroconversion. No male donors seroconverted during 9 months of follow up. Pregnant individuals with seroconversion were more likely to have systemic lupus erythematosus and antiphospholipid antibody syndrome.
Discussion
Only one pregnant individual developed clinically significant alloantibodies within 72 h of a negative screening, compared to none of the control group. For pregnant individuals without recent transfusion, extending antibody screening intervals to 1 week appears safe.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Helen Schneider Hospital for Women, Rabin Medical Center, Petach Tikva, Israel.
- Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Blood Services & Apheresis Institute, Rabin Medical Center, Petach Tikva, Israel.
- School of Public Health, Tel Aviv University, Tel Aviv, Israel.
ORCID-Profile: E Dreyfuss, V Yahalom, O Houri
Zitieren
APA
Dreyfuss, E., Yahalom, V., Barer, Y., Ambar, I., Pardo, A., Shmueli, A., Houri, O., Hadar, E., & Barbash-Hazan, S. (2025). The prevalence and timing of seroconversion during pregnancy—A retrospective study to enable safe transfusion. Transfusion. https://doi.org/10.1111/trf.18356
Vancouver
Dreyfuss E, Yahalom V, Barer Y, Ambar I, Pardo A, Shmueli A, et al. The prevalence and timing of seroconversion during pregnancy—A retrospective study to enable safe transfusion. Transfusion. 2025. doi:10.1111/trf.18356
BibTeX
@article{Dreyfuss2025,
author = {Dreyfuss, E and Yahalom, V and Barer, Y and Ambar, I and Pardo, A and Shmueli, A and Houri, O and Hadar, E and Barbash-Hazan, S},
title = {The prevalence and timing of seroconversion during pregnancy—A retrospective study to enable safe transfusion},
journal = {Transfusion},
year = {2025},
doi = {10.1111/trf.18356}
}
EUVIMED